Ceapro, IR2Dx to work on pre-diabetes screening test
This article was originally published in Clinica
Executive Summary
Canadian biotech firm Ceapro is set to develop its CeaProve point-of-care, pre-diabetes screening test alongside IR2Dx, a company specialising in metabolic diagnostics. The two firms have signed a research and commercial development agreement, which will see a clinical research project established in Germany and Canada to demonstrate CeaProve’s superiority over existing glucose tolerance technology.